On Tuesday, Shares of Petróleo Brasileiro S.A. - Petrobras (NYSE:PBR), gained 2.84% to $9.05, as oil prices raised as a result of lower shale oil production forecasts.
Brent crude settled up $US2.19 a barrel, or 3.5 per cent, at $64.88, and US crude settled up $US2 a barrel, or 3.44 per cent, at $US60.14.
Petróleo Brasileiro S.A. Petrobras operates as an integrated energy company in Brazil and internationally. Its Exploration and Production segment engages in the exploration, development, and production of crude oil, natural gas liquids, and natural gas; and sale of crude oil and oil products produced at natural gas processing plants in domestic and foreign markets.
Shares of AbbVie Inc. (NYSE:ABBV), declined -0.18% to $67.67, during its last trading session.
AbbVie, launched its second annual Week of Possibilities volunteer program, with 3,100 employees globally volunteering more than 14,000 service hours to transform schools and communities where AbbVie employees live and work.
For 2015, the program comprises more than 39 countries and more than 55 separate hands-on service projects, with a special emphasis on transforming education in ways that will improve the lives of those in underserved populations.
“In many communities, children face a noteworthy achievement gap in science and literacy,” said Richard A. Gonzalez, chairman and chief executive officer of AbbVie. “We are committed to assisting narrow that gap to empower all the students of recently to become the scientists of tomorrow.”
AbbVie launched Week of Possibilities in 2014 as a local initiative in which employees volunteered more than 6,800 hours to renovate schools and other learning facilities and provide educational materials to students in North Chicago, Ill., and Worcester, Mass. This year, the program has been expanded to comprise projects in Australia, Brazil, China, Italy, Japan, Turkey, Russia and 31 other countries.
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceutical products worldwide. The company’s products comprise HUMIRA, a biologic therapy administered as a subcutaneous injection to treat autoimmune diseases; VIEKIRA PAK, an all-oral, short-course, interferon-free therapy, with or without ribavirin, for adult patients with genotype 1 chronic hepatitis, counting those with compensated cirrhosis; Kaletra, an anti-HIV-1 medicine used with other anti-HIV-1 medications as a treatment that maintains viral suppression in people with HIV-1.
Finally, Baxter International Inc. (NYSE:BAX), ended its last trade with -0.71% loss, and closed at $64.08, hitting its lowest level.
CTI BioPharma Corp. and Baxter International’s BioScience business declared that Patient Stated Outcomes (PROs) data from the Phase 3 PERSIST-1 trial, evaluating pacritinib in patients with myelofibrosis, will be highlighted in a late-breaking oral presentation at the forthcoming 20th Congress of the European Hematology Association (EHA), June 11-14, Vienna. Pacritinib is an investigational oral multikinase inhibitor with specificity for JAK2 and FLT3. These data were also selected for inclusion in the official EHA Press Briefing on Friday, June 12, 2015 at 08:30 CEST.
Myelofibrosis is associated with significantly reduced quality of life and shortened survival. As the disease progresses, the body slows production of important blood cells and within one year of diagnosis the incidence of disease-related thrombocytopenia (very low blood platelet counts), severe anemia, and red blood cell transfusion requirements enhance significantly. Among other complications, most patients with myelofibrosis present with enlarged spleens (splenomegaly) in addition to many other potentially devastating physical symptoms such as: abdominal discomfort, bone pain, feeling full after eating little, severe itching, night sweats, and tiredness.
Baxter International Inc., develops, manufactures, and markets products for people with hemophilia, immune disorders, infectious diseases, kidney disease, trauma, and other chronic and acute medical conditions. The company’s BioScience segment processes recombinant and plasma-based proteins to treat hemophilia and other bleeding disorders.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should/might occur.
